**Supporting Information**

**Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids**

Laxman Subedia\*, Prashant Pandeya\*, Bikram Khadkaa, Jung-Hyun Shima,b, Seung-Sik Choa,b, Seho Kweonc, Youngro Byunc,d, Ki-Taek Kima,b and Jin Woo Parka,b

aDepartment of Biomedicine, Health & Life Convergence Sciences, BK21 Four, Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam 58554 Republic of Korea

bCollege of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea

cDepartment of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

dResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

\* Laxman Subedi and Prashant Pandey contributed equally to this work as first authors.

**Addresses for correspondences:** Ki-Taek Kim, E-mail: [ktkim0628@mnu.ac.kr](mailto:ktkim0628@mnu.ac.kr), Department of Pharmacy, College of Pharmacy, Mokpo National University, 1666 Youngsan-ro, Muan-gun, Jeonnam 58554, Republic of Korea; Jin Woo Park, E-mail: [jwpark@mokpo.ac.kr](mailto:jwpark@mokpo.ac.kr), Department of Pharmacy, College of Pharmacy, Mokpo National University, 1666 Youngsan-ro, Muan-gun, Jeonnam 58554, Republic of Korea

**Running head:** Enhanced oral absorption of atorvastatin for chemotherapy

**Table S1.** Inhibitors and concentrations used in the transport study, listed with their functions.

|  |  |  |
| --- | --- | --- |
| Inhibitor | Concentration | Function |
| Act D | 3.2 μM | Inhibitor of ASBT-mediated transport |
| CFZ | 10 μM | Inhibitor of OSTα/β blocking the transport of bile acid across the basolateral membrane |
| PA | 0.2 mM | Inhibition of SMVT-mediated transport |
| Chlorpromazine | 32 μM | Inhibitor of clathrin-mediated endocytosis |
| MBCD | 10 mM | Inhibitor of caveola/lipid raft-mediated endocytosis (cholesterol depletion) |
| Genistein | 0.1 mM | Inhibitor of caveola/lipid raft-mediated endocytosis (broad inhibitor of protein tyrosine kinase) |
| Amiloride | 0.1 mM | Inhibitor of macropinocytosis |
| Brefeldin A | 90 μM | Inhibitor of ER/Golgi pathway |
| Cys A | 10 µM | Inhibitor of P-gp-mediated efflux |

Act D, actinomycin D; ASBT, apical sodium-dependent bile acid transporter; CFZ, clofazimine; OSTα/β, organic solute transporter α and β; PA, pantothenic acid; SMVT, sodium-dependent multivitamin transporter; MBCD, methyl-β-cyclodextrin; ER, endoplasmic reticulum; Cys A, cyclosporine A; P-gp, P-glycoprotein.